JP2019512020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512020A5 JP2019512020A5 JP2018561191A JP2018561191A JP2019512020A5 JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5 JP 2018561191 A JP2018561191 A JP 2018561191A JP 2018561191 A JP2018561191 A JP 2018561191A JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- days
- use according
- inhibitor
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022064122A JP2022088665A (ja) | 2016-02-12 | 2022-04-07 | がんの治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294349P | 2016-02-12 | 2016-02-12 | |
| US62/294,349 | 2016-02-12 | ||
| US201662404252P | 2016-10-05 | 2016-10-05 | |
| US62/404,252 | 2016-10-05 | ||
| PCT/US2017/017445 WO2017139628A1 (en) | 2016-02-12 | 2017-02-10 | Cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022064122A Division JP2022088665A (ja) | 2016-02-12 | 2022-04-07 | がんの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512020A JP2019512020A (ja) | 2019-05-09 |
| JP2019512020A5 true JP2019512020A5 (enExample) | 2020-03-26 |
Family
ID=59088211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561191A Ceased JP2019512020A (ja) | 2016-02-12 | 2017-02-10 | がんの治療 |
| JP2022064122A Pending JP2022088665A (ja) | 2016-02-12 | 2022-04-07 | がんの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022064122A Pending JP2022088665A (ja) | 2016-02-12 | 2022-04-07 | がんの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US11000578B2 (enExample) |
| EP (1) | EP3413927A4 (enExample) |
| JP (2) | JP2019512020A (enExample) |
| CN (1) | CN108883203A (enExample) |
| AU (1) | AU2017217940B2 (enExample) |
| CA (1) | CA3013930C (enExample) |
| HK (1) | HK1258319A1 (enExample) |
| WO (1) | WO2017139628A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN112638947B (zh) * | 2018-08-30 | 2022-09-30 | 上海斯丹赛生物技术有限公司 | 用于治疗实体瘤的嵌合抗原受体细胞 |
| WO2020097209A1 (en) * | 2018-11-06 | 2020-05-14 | Wisconsin Alumni Research Foundation | Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor |
| CN109593135B (zh) * | 2018-12-29 | 2021-01-15 | 百奥赛图江苏基因生物技术有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20220133873A1 (en) * | 2019-02-08 | 2022-05-05 | Madison Vaccines Inc. | Cancer therapy |
| CN110632292A (zh) * | 2019-06-12 | 2019-12-31 | 江苏莱尔生物医药科技有限公司 | 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法 |
| WO2021108331A1 (en) * | 2019-11-26 | 2021-06-03 | The Regents Of The University Of California | Combination therapy for head and neck cancer |
| CN111141906A (zh) * | 2020-01-06 | 2020-05-12 | 中南大学湘雅医院 | 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒 |
| EP4175664A2 (en) * | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP2025500494A (ja) | 2021-12-23 | 2025-01-09 | ユニフェルシテイト マーストリヒト | 免疫防護型の植込み可能な細胞送達デバイス |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2001025272A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7179797B2 (en) * | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
| US20070232558A1 (en) | 2006-03-31 | 2007-10-04 | Mcneel Douglas G | Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen |
| US7910565B2 (en) | 2006-09-01 | 2011-03-22 | Wisconsin Alumni Research Foundation | Prostate cancer vaccine |
| JP2010504356A (ja) | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法 |
| WO2008073660A1 (en) | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2008103645A2 (en) | 2007-02-19 | 2008-08-28 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| ES2608604T3 (es) | 2007-10-18 | 2017-04-12 | Bavarian Nordic A/S | Uso de MVA para tratar el cáncer de próstata |
| ES2660597T3 (es) * | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| WO2011130742A2 (en) | 2010-04-16 | 2011-10-20 | Wisconsin Alumni Research Foundation | Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens |
| US8603485B2 (en) | 2011-01-05 | 2013-12-10 | Wisconsin Alumni Research Foundation | Bystander immune suppression as a predictor for response to a vaccine |
| PL2844282T3 (pl) * | 2012-05-04 | 2019-11-29 | Pfizer | Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce |
| WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| JP2017535599A (ja) | 2014-11-07 | 2017-11-30 | ウィスコンシン アラムニ リサーチ ファンデーション | Ｂ細胞標的ｄｎａワクチン |
| WO2016094639A1 (en) | 2014-12-10 | 2016-06-16 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid dna vaccines in combination with lag3 blockade |
| WO2017139755A1 (en) * | 2016-02-12 | 2017-08-17 | Rekoske Brian T | Cancer therapy |
-
2017
- 2017-02-10 JP JP2018561191A patent/JP2019512020A/ja not_active Ceased
- 2017-02-10 HK HK19100687.7A patent/HK1258319A1/zh unknown
- 2017-02-10 WO PCT/US2017/017445 patent/WO2017139628A1/en not_active Ceased
- 2017-02-10 CA CA3013930A patent/CA3013930C/en active Active
- 2017-02-10 CN CN201780018603.6A patent/CN108883203A/zh active Pending
- 2017-02-10 AU AU2017217940A patent/AU2017217940B2/en not_active Expired - Fee Related
- 2017-02-10 EP EP17750860.3A patent/EP3413927A4/en not_active Withdrawn
- 2017-02-10 US US15/430,012 patent/US11000578B2/en active Active
- 2017-02-13 US US16/077,680 patent/US20190030150A1/en not_active Abandoned
-
2021
- 2021-05-06 US US17/313,335 patent/US11806391B2/en active Active
-
2022
- 2022-04-07 JP JP2022064122A patent/JP2022088665A/ja active Pending
-
2023
- 2023-10-23 US US18/492,311 patent/US20240115684A1/en not_active Abandoned
-
2024
- 2024-11-15 US US18/948,989 patent/US20250074987A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7712970B2 (ja) | ホットスポットを利用した新生抗原の特定 | |
| Pandya et al. | The future of cancer immunotherapy: DNA vaccines leading the way | |
| JP7480064B2 (ja) | パンアレルモデルによる新生抗原の特定方法 | |
| Molodtsov et al. | Tissue resident CD8 memory T cell responses in cancer and autoimmunity | |
| Zhu et al. | Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions? | |
| Zhang et al. | Personalized cancer vaccines: Targeting the cancer mutanome | |
| JP2021176866A (ja) | 共通ネオ抗原 | |
| Liu et al. | Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective | |
| JP2020169177A (ja) | ネオエピトープワクチン組成物及びその使用方法 | |
| TWI893039B (zh) | 透過循環腫瘤dna分析之分子疾病評估之方法及系統 | |
| Medler et al. | Defining immunogenic and radioimmunogenic tumors | |
| JP2017524337A5 (enExample) | ||
| JP2012515213A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| JP2023516954A (ja) | 遺伝子サンプリングにおける統計的バイアスの軽減 | |
| Pilla et al. | Methods for improving the immunogenicity and efficacy of cancer vaccines | |
| Liu et al. | Immune-based therapy clinical trials in hepatocellular carcinoma | |
| CN106243213A (zh) | 一种肿瘤相关抗原XAGE‑1b短肽及应用 | |
| Chen et al. | Viral‐Directed Augmentation of Kupffer Cell Cross‐Presentation Provokes Antitumor Immunity Against Liver Metastasis | |
| Zhang et al. | Age-related differences in molecular profiles for immune checkpoint blockade therapy | |
| Banday et al. | From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy | |
| Yang et al. | An engineered influenza A virus expressing the co-stimulator OX40L as an oncolytic agent against hepatocellular carcinoma | |
| Fousteri et al. | Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure | |
| US20180133270A1 (en) | Recombinant oncolytic viruses and uses thereof | |
| Kato et al. | RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer |